Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

Apr 20, 2018

SELL
$8.1 - $16.0 $2,025 - $4,000
-250 Closed
0 $0
Q4 2017

Feb 22, 2018

SELL
$10.5 - $14.15 $7,875 - $10,612
-750 Reduced 75.0%
250 $4,000
Q3 2017

Oct 27, 2017

BUY
$7.7 - $11.55 $7,700 - $11,550
1,000
1,000 $11,000

Others Institutions Holding EIGR

About Eiger BioPharmaceuticals, Inc.


  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $418M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Cable Hill Partners, LLC Portfolio

Follow Cable Hill Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cable Hill Partners, LLC with notifications on news.